Investigation of the Effect of BONISTEIN(R) Bone Blend on Bone Mineral Density/Content and Biomarkers of Bone Health

Inclusion Criteria: * Female * Age 45 (inclusive) to 55 years (inclusive) * Race: Caucasian * Non-smokers / Smokers up to 10 cigarettes/day * Postmenopausal hormone status: 1-3 years since the last spontaneous menstrual bleeding and a follicle-stimulating hormone concentration (FSH) \>75 IU/ml and 17-estradiol (E2) of \< 20 ng/L * Years since menopause between 1-3 years * Natural menopause or total hysterectomy with bilateral salpingo-oophorectomy * Subjects with E2 results within the inclusion criteria range will be assessed on an individual basis if FSH level is less than 75 IU/ml * Assessed as age-related healthy, based on a pre-study examination including medical history, physical examination, ECG, vital signs and clinical laboratory. The examination will be performed by a MD at the study site within 1-2 months prior planned study start for the individual subject. * Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements. * Ability to understand, speak, read and write the English language Exclusion Criteria: * T-score \< -2.5 at total hip and spine (either or both) * Suspect lack of compliance * BMI \> 30 or \< 21 * Use of HRT within the previous 6 months * Use of any drug which might interfere with bone-metabolism (bisphosphate, estrogen receptor modulators, calcitonin) within the previous 12 months * Systematic practice of high intensity exercise * Vegetarian nutrition or any other extreme dietary habits * Use of dietary supplements while on study, except multi vitamin. No "wash out" period for supplements - must stop before run-in period and refrain until the end of the study. * Participant in any other study or donation of blood during the last 30 days before start of each dosing phase (T0). * Total genistein blood concentrations of \> 100 ng/ml measured at pre-study examination * Known hypersensitivity or allergy to soy, purified isoflavones, peanuts, fish, and/or genistein. * Hepatitis screen (serology) positive or not performed * Drug screen positive or not performed (at least amphetamines, benzodiazepines, cannabinoides, opiates). * Subjects on a weight reduction program or a medically supervised diet * Unexplained weight loss or weight gain of more than 5 kg in the three months prior to the study * History of liver or pancreas diseases * Cardiovascular diseases, even AV-block I0 (PQ time \> 220 ms) and QTc time \> 450 ms * History of breast cancer, endometrial cancer and other malignancy except basal and squamous cell skin cancer * History of thromboembolism or deep venous thrombosis * Any fractures within one year except for fingers, toes and facial bones * Subjects with susceptibility for fractures as a history of being a faller * Endometrial thickness \> 6 mm * Endometrial polyps * Untreated hypo- or hyperthyroidism * Insulin-dependent diabetes mellitus, Crohn's Disease, Cushing Disease etc. * Any condition which might interfere with absorption of the investigational product (e.g. malabsorption syndrome) * Co-medication: Anticoagulants, parathyroid hormones, corticosteroids, thiazide diuretic * Subjects who, during the previous 24 months, received a total fee payment greater than 5'000 USD for participation in biomedical research